文献速递湿疹皮炎与荨麻疹

慢性荨麻疹管理:现状与未来展望

Management of chronic urticaria: Current status and future prospect.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-09-08

慢性荨麻疹是肥大细胞驱动的炎症性疾病,以反复风团和/或血管性水肿超过6周为特征,严重影响睡眠、生活质量及心理健康。当前管理强调确诊、排除鉴别诊断、识别加重因素与合并症,并使用患者报告结局工具监测疾病活动与控制。第二代H1抗组胺药仍为一线治疗,奥马珠单抗、度普利尤单抗和瑞布替尼等新药拓展了治疗选择,未来趋向生物标志物驱动的个体化诊疗。

要点

  • 慢性荨麻疹诊断需确认风团和/或血管性水肿持续超过6周,并排除鉴别诊断。
  • 第二代H1抗组胺药为一线治疗,应答不足者可上调剂量。
  • 奥马珠单抗用于抗组胺药难治性病例,环孢素对重症患者仍有效但需安全监测。

核心结论

  • 慢性荨麻疹管理应基于诊断确认、加重因素识别和患者报告结局监测,治疗以第二代H1抗组胺药为一线,奥马珠单抗等新药拓展了难治性患者的治疗选择。

主要发现

  • I型自身过敏和IIb型自身免疫机制是主要内型,但许多患者表现重叠或混合特征,导致临床病程异质和治疗反应差异。
  • 二代H1抗组胺药应答不足时推荐上调剂量,奥马珠单抗改变了抗组胺药难治性疾病的治疗。
  • 环孢素对重症或难治性患者仍有效,但需仔细安全监测。

关键数值与推荐

  • 慢性荨麻疹定义为反复风团、血管性水肿或两者兼有持续超过6周。
  • 诊断检查应有限且临床导向,扩展检查仅保留给基于病史、检查、红flag或孤立性血管性水肿的选定病例。
  • 慢性诱导性荨麻疹的管理核心包括激发试验、阈值评估、触发因素咨询和个体化治疗。

临床怎么用

  • 临床应使用经验证的患者报告结局工具监测疾病活动和控制水平。
  • 对二代H1抗组胺药应答不足者,可上调剂量,仍难治者考虑奥马珠单抗等生物制剂。
  • 环孢素可用于重症或难治性患者,但需密切监测安全性。

局限性

  • 缺乏可靠的内型分型生物标志物,新兴疗法的循证选择依据不足。
  • 儿童和其他特殊人群的数据有限,缓解和复发的标准化定义尚未统一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic urticaria is a mast cell-driven inflammatory disease characterized by recurrent wheals, angioedema or both for more than 6 weeks, with substantial effects on sleep, quality of life, mental health and daily functioning. Type I autoallergic and type IIb autoimmune mechanisms represent major endotypes, but many patients show overlapping or mixed features, contributing to heterogeneous clinical courses and variable treatment responses. Current management relies on confirming the diagnosis, excluding differential diagnoses, identifying aggravating factors and comorbidities and monitoring disease activity and control using validated patient-reported outcome measures. A limited, clinically guided diagnostic workup is preferred, with extended investigations reserved for selected cases based on history, examination, red flags or isolated angioedema. Second-generation H1-antihistamines remain the first-line therapy, with up-dosing recommended in insufficient responders. Omalizumab has transformed the treatment of antihistamine-refractory disease, while newer options such as dupilumab and remibrutinib further expand the therapeutic landscape. Ciclosporin remains an effective option in selected patients, particularly those with severe or difficult-to-treat disease, but requires careful safety monitoring. In chronic inducible urticaria, provocation testing, threshold assessment, trigger counselling and individualized treatment are central to care. Despite recent advances, important unmet needs remain, including reliable biomarkers for endotyping, evidence-based selection among emerging therapies, better data in children and other special populations, standardized definitions of remission and relapse and disease-modifying strategies. Future management is expected to move towards biomarker-driven, personalized care, enabling more precise treatment selection and sustained disease control.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Salman A, Al-Ahmad M, Al-Nesf M, et al. Management of chronic urticaria: Current status and future prospect. J Eur Acad Dermatol Venereol. 2026. PMID: 42712073. doi:10.1111/jdv.70637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。